Markers of tissue aging and uses therefor

JP2024161422A5Inactive Publication Date: 2024-12-05UNIV OF NEWCASTLE RES ASSOCS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024126677
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-03-03
Filing Date
2024-08-02
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods lack the ability to accurately predict the risk of stillbirth and determine the optimal gestational age for delivery, as the cause of stillbirth is often unknown and there are no effective biomarkers for placental oxidative stress.

Method used

The use of aldehyde oxidase 1 (AOX1) expression and activity levels, along with markers such as 4-hydroxynonenal (4HNE), to detect placental oxidative stress and aging, allowing for the prediction of stillbirth risk and determination of appropriate delivery time.

Benefits of technology

Provides a non-invasive method to assess placental health and predict stillbirth risk, enabling interventions like caesarean section or induction of labor to prevent stillbirth, and offers a means to slow or prevent tissue aging through inhibitors like raloxifene or G protein-coupled estrogen receptor 1 (GPER1) agonists.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

To provide methods of detecting or determining aging and / or oxidative damage in tissue, including placental tissue, skin, kidney and brain tissue.SOLUTION: Provided herein are methods of detecting or determining aging and / or oxidative damage in tissue, including placental tissue, skin, kidney and brain tissue. One embodiment provides a method for detecting or determining aging in body tissue, comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample. The level of AOX1 expression or activity, or of the one or more markers, is indicative of aging in the tissue. Also provided herein are methods of treating a disease or condition associated with ageing or oxidative damage in one or more cells or tissues, comprising administering to a subject in need thereof an inhibitor of AOX1.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates generally to methods for detecting or determining aging and / or oxidative damage in tissues, such as placental tissue, skin, kidney, and brain tissue. The present disclosure also relates to methods for delaying, slowing, or preventing aging and / or oxidative damage in such tissues. [Background technology]

[0002] Accumulated random damage to tissues can affect tissue function and contribute to aging. Metabolic processes and cell proliferation generate reactive oxygen species that can damage proteins, lipids, and nucleic acids. Cells are equipped with defense mechanisms against oxidative stress, such as enzymes such as catalase and superoxide dismutase, but when repair mechanisms are insufficient to compensate for the generation of reactive oxygen species, tissue damage and aging can occur.

[0003] Proliferative pathways are generally associated with increased oxidative stress. Due to the placenta's ability to promote fetal growth, it is not surprising that indicators of oxidative damage may appear in the placenta, especially near the end of pregnancy when fetal growth is rapid. We hypothesized that stillbirth may be related to a reduced ability of the aging placenta to support the fetus (Smith et al 2013, Placenta, 34:310-313). In support of this view, histopathological studies of placentas associated with cases of unexplained intrauterine death at term revealed that 91% showed thickening of the maternal spiral artery walls, 54% contained placental infarction, 10% had areas of calcification, and 13% had vascular occlusion; changes associated with aging of other organs. We demonstrated that placentas from women with delayed or stillbirth have biochemical evidence of aging and oxidative stress.

[0004] Unexplained fetal death is a common complication of pregnancy, occurring in approximately 1 in 200 pregnancies in developed countries and more frequently in developing countries. Unexplained fetal death is 40 times more common than sudden infant death syndrome, yet receives little attention. However, the event is devastating to the families involved. Although the cause is not determined, stillbirth may be related to fetal growth restriction, congenital anomalies, antepartum hemorrhage, perinatal infections, preeclampsia, and maternal factors such as maternal height and age, obesity, hypertension, diabetes, smoking, parental consanguinity, ethnicity, and country of birth. Although risk factors for stillbirth exist, the cause often remains unknown.

[0005] In some antepartum cases, the fetus may stop moving before stillbirth, but in some cases there may be no warning signs. A lack of understanding of the causes of stillbirth makes it difficult to predict risk during pregnancy. Stillbirth can be defined as the death of a fetus before or during birth at 20 weeks or more of gestation or birth weight 400g or more (Perinatal Society of Australia and New Zealand Clinical Practice Guideline for Perinatal Mortality; Second Edition, version 2.2, April 2009). Identifying indicators of risk of stillbirth could provide pregnant women with the opportunity to undergo prophylactic caesarean section or induction of labour to reduce risk to the fetus. Therefore, diagnostic biomarkers of risk of stillbirth should be highly beneficial in preventing stillbirth.

[0006] The optimal length of pregnancy may vary between individuals. In the case of preterm birth, the infant may be viable, but complications are likely if it is not adequately developed in utero. In general, longer gestational ages (up to approximately 41 weeks) are associated with better development of the infant's anatomical and physiological systems. In fact, infants born at 41 weeks gestation are less likely to require special education later in life than infants born at 37 weeks gestation. However, prolonged gestational ages can result in post-maturity symptoms, where the fetus continues to grow and requires additional supplies of nutrients. Post-maturity syndrome is a condition seen in post-dated infants who show evidence of malnutrition in the later stages of pregnancy. Normal human infants born at term have 12-14% body fat, but post-maturity syndrome is associated with the birth of infants with severely wrinkled skin due to a lack of subcutaneous fat. Post-maturity pregnancy syndrome is rarely seen in modern obstetric practice, where delivery usually occurs before 42 weeks of gestation, using induction of labor or Caesarean section if labor does not occur naturally. In particular, the risk of stillbirth increases significantly in post-term pregnancies, with the rate rising exponentially beyond 38 weeks of gestation. Thus, although there appears to be an optimal gestational age for pregnancy, this age is likely to vary between individuals. Currently, there is no method to determine the ideal gestational age for an individual pregnancy. Although placental aging may be an indicator of the appropriate time to deliver, there is currently no method to determine the oxidative status of a pregnant woman's placenta with minimal risk to the fetus. Summary of the Invention [Means for solving the problem]

[0007] The present disclosure is based on the inventors' surprising discovery that the expression and activity of aldehyde oxidase 1 (AOX1) (and its marker levels, such as 4-hydroxynonenal, 4HNE) correlates with tissue aging and oxidative damage in multiple tissues, including placenta and kidney. The inventors have also demonstrated that placental oxidative stress can be reduced by administration of an inhibitor of AOX1, such as raloxifene, or a G protein-coupled estrogen receptor 1 (GPER1) agonist, such as G1. As illustrated herein, inhibition of AOX1 prevents oxidative and lysosomal changes in placental tissue.

[0008] Thus, the present inventors have identified an effective biomarker that can be sampled non-invasively to obtain an indication of placental oxidative stress, which indicates that pregnancy may be at risk of stillbirth.Oxidative and lysosomal changes similar to those observed in the placenta can also be seen in age-related diseases (e.g., Alzheimer's disease, Huntington's disease).AOX1 therefore also provides a marker of oxidative damage and aging in multiple tissue types, and a target for their treatment or prevention.

[0009] A first aspect of the present disclosure provides a method for detecting or determining aging of a body tissue, the method comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample obtained from a subject, wherein the level of AOX1 expression or activity determined by the level of the one or more markers is indicative of aging of the tissue.

[0010] In one embodiment, the tissue is selected from placental tissue, skin, kidney, or brain tissue.

[0011] In an exemplary embodiment, the subject is pregnant and the tissue is placental tissue.

[0012] The biological sample may be, for example, a sample of the relevant tissue, or a liquid sample such as blood (whole blood, plasma, or serum), urine, saliva, or amniotic fluid. In embodiments in which the subject is pregnant, the sample may include, for example, maternal blood, fetal blood, urine, saliva, or amniotic fluid. In embodiments in which the subject is pregnant, the biological sample is typically from the mother, and optionally maternal blood. In other embodiments in which the subject is pregnant, the biological sample may include derivatives of samples from the pregnant subject, placental tissue, and / or fetus, such as total RNA from maternal blood, which total RNA may be maternal, placental, or fetal.

[0013] One or more markers of AOX1 expression or activity can be measured from substances released from senescent tissue into blood.In an embodiment in which the subject is pregnant, one or more markers of AOX1 expression or activity can be measured from substances released from senescent placental tissue into maternal blood.Therefore, one or more markers can be measured in maternal blood.In an exemplary embodiment, one or more markers are derived from free RNA or free DNA, placental cell fragments, exosomes, or microparticles present in biological sample.

[0014] The expression of AOX1 can be measured at the mRNA or gene level, or at the polypeptide or protein level. In an exemplary embodiment, a suitable marker of AOX1 expression or activity can include AOX1 mRNA. In other embodiments, a suitable marker of AOX1 expression or activity can include a downstream molecule of AOX1, such as a lipid peroxidation product. Exemplary lipid peroxidation products are 4-hydroxynonenal (4HNE) and malondialdehyde (MDA). Other products of oxidative damage that can be measured can include 8-hydroxy-deoxyguanosine (8OHdG), 8-hydroxyguanosine (8HOG). In an exemplary embodiment, any two or more markers of AOX1 expression or activity can be determined or measured in combination. For example, AOX1 mRNA can be measured in combination with a lipid peroxidation product, such as 4HNE.

[0015] Typically, the expression or activity level of AOX1 in a subject, determined by one or more markers, is compared with one or more reference values ​​of AOX1 expression or activity in tissues that do not have oxidative damage, or one or more markers thereof. Reference values ​​can be obtained or derived from one or more control or reference individuals. Alternatively, reference values ​​can be derived from one or more biological samples obtained from a subject at different time points, and can be used as a baseline value to which further biological samples from the subject can be compared. Those skilled in the art will be familiar with how to determine and select suitable reference samples.

[0016] Typically, the increase in the expression or activity of AOX1 or one or more markers thereof in the biological sample from the subject compared to the reference value indicates oxidative stress and / or aging of tissue. In an exemplary embodiment, the tissue is placental tissue and the biological sample is maternal blood.

[0017] In certain embodiments, additional markers of oxidative stress, such as placental or fetal oxidative stress, can also be measured in the biological sample or in the further biological sample. Non-limiting examples of such additional markers of oxidative damage or oxidative stress can include AOX1 protein, glutathione, or protein carbonyl.

[0018] In embodiments in which the subject is pregnant, the method can be performed one or more times at any time during pregnancy, particularly during the later stages of pregnancy, such as at about week 20 of pregnancy for human subjects. In certain embodiments, the method can be performed during a post-dated pregnancy, for example, at or after week 40 of pregnancy for human subjects.

[0019] A particular application of the method of the present disclosure is to detect placental aging in a pregnant subject to predict the risk of stillbirth, and an increase in the level of AOX1 expression or activity or one or more markers thereof in a biological sample compared to a reference value indicates placental aging and the risk of stillbirth. Placental aging can be associated with oxidative damage to the placenta and / or fetus, poor fetal health, and increased risk of stillbirth. Placental oxidative stress and placental aging can also be associated with insufficient transfer of nutrients to the fetus. This method can also be used to diagnose preeclampsia in a pregnant subject or to diagnose intrauterine growth retardation of the fetus. This method can also be used to predict the risk of overdue pregnancy or can be associated with overdue pregnancy.

[0020] Further embodiments of the present disclosure include obtaining a biological sample from a pregnant subject and measuring one or more markers of placental AOX1 expression or activity in the biological sample to determine the need for intervention to prevent stillbirth during pregnancy, where increased AOX1 expression or activity or the level of one or more markers thereof compared to a reference value indicates that an intervention may be required. Such intervention may include prophylactic Caesarean section, induction of labor, and / or administration of a treatment to prevent or delay placental aging or prolong intrauterine fetal survival. Thus, in one embodiment, the method can be used to determine the appropriate time to deliver a child by determining whether placental oxidative stress is at a level that exposes the fetus to a risk of stillbirth. Increased AOX1 expression or activity or the level of one or more markers thereof compared to a reference value may suggest or indicate the appropriate time to deliver a child.

[0021] In one embodiment, the method of the present disclosure can be used to monitor the risk of stillbirth during pregnancy by detecting or determining the aging of placental tissue by measuring one or more markers of AOX1 expression or activity in one or more biological samples obtained from a subject over time.In such a method, biological samples are obtained from a subject during pregnancy at multiple time points during pregnancy, for example every two weeks, every week, or every day, and one or more markers of placental AOX1 expression or activity are measured in each biological sample at each time point.An increase in the level of AOX1 expression or activity or one or more markers thereof over time can indicate an increased risk of stillbirth and thus the need for intervention to prevent stillbirth.

[0022] A second aspect of the present disclosure provides a method for detecting placental aging, the method comprising obtaining a biological sample from a pregnant subject and measuring one or more markers of placental AOX1 expression or activity in the biological sample, wherein the level of AOX1 expression or activity or the one or more markers thereof is indicative of placental aging.

[0023] Typically, an increased expression or activity of AOX1 or the level of one or more markers thereof compared to the reference value indicates placental aging. A suitable reference value can be derived or obtained from a sample from one or more individual tissues whose placental tissue does not show signs of oxidative damage, or can be derived or obtained from a subject at an earlier time point during pregnancy.

[0024] Placental aging may be associated with an increased risk of stillbirth, pre-eclampsia, fetal growth restriction, and / or increased risk of post-term pregnancy.

[0025] A third aspect of the present disclosure provides a method for predicting the risk of stillbirth during pregnancy, the method comprising obtaining a biological sample from a pregnant subject and measuring one or more markers of placental AOX1 expression or activity in the biological sample, wherein the level of AOX1 expression or activity or the one or more markers thereof is indicative of the risk of stillbirth.

[0026] The risk of stillbirth can be determined directly or indirectly. For example, the expression or activity of AOX1 or the level of one or more markers thereof can be an indicator of increased risk of preeclampsia, fetal intrauterine growth restriction, and / or overdue pregnancy, which are indicators or factors associated with increased risk of stillbirth, respectively.

[0027] Typically, the expression or activity of AOX1 or the level of one or more markers thereof, which is increased compared to the reference value, indicates the risk of stillbirth.The reference value can be obtained or derived from one or more control or reference individuals.Suitable reference values ​​can be derived or derived from samples from tissues of one or more individuals whose placental tissue does not show signs of oxidative damage, or can be derived or derived from subjects at an earlier time point during pregnancy.

[0028] Thus, a fourth aspect of the present disclosure provides a method for determining the need for intervention to prevent overdue pregnancy or stillbirth during pregnancy, the method comprising obtaining a biological sample from a pregnant subject and measuring one or more markers of placental aldehyde oxidase 1 (AOX1) expression or activity in the biological sample, wherein the level of AOX1 expression or activity or the one or more markers thereof is indicative of the need for intervention.

[0029] The intervention may include at least one of the following: preventive Caesarean section, induction of labor, or administration of a treatment to delay placental aging or prolong intrauterine fetal survival. If the fetus is too immature to be safely delivered or too slow in development to survive, the intervention may include a targeted treatment to reduce oxidative stress or AOX1 expression or activity, as discussed in further aspects and embodiments of the present disclosure.

[0030] A fifth aspect of the present disclosure provides a method for detecting placental oxidative stress, the method comprising obtaining a biological sample from a pregnant subject and measuring one or more markers of placental AOX1 expression or activity in the biological sample, wherein the level of AOX1 expression or activity or the one or more markers thereof is indicative of placental oxidative stress.

[0031] Typically, the expression or activity of AOX1 or the level of one or more markers thereof, which is increased compared to the reference value, indicates oxidative stress in the placenta.The reference value can be obtained or derived from one or more control or reference individuals.Suitable reference values ​​can be derived or derived from samples from tissues of one or more individuals whose placental tissues do not show signs of oxidative damage, or can be derived or derived from subjects at earlier time points during pregnancy.

[0032] A sixth aspect of the present disclosure provides a method for monitoring placental aging, placental oxidative stress, or risk of overdue pregnancy or stillbirth during pregnancy, the method comprising: (i) obtaining a biological sample from a pregnant subject at an early time point during pregnancy; (ii) measuring one or more markers of placental AOX1 expression or activity in the biological sample; (iii) obtaining one or more further biological samples from the subject at one or more later time points during pregnancy; and (iv) measuring one or more markers of placental AOX1 expression or activity in the one or more further biological samples, wherein an increase in the level of AOX1 expression or activity or the one or more markers thereof over time is indicative of placental aging, placental oxidative stress, or risk of overdue pregnancy or stillbirth.

[0033] Measurement of one or more markers can begin, for example, in mid-pregnancy. In an exemplary embodiment, the biological sample can be obtained at about 20 weeks of gestation. The interval between time points can be determined by one skilled in the art and can be daily, weekly, biweekly, monthly, or another suitable period as determined by the practitioner. Time points can increase in frequency throughout pregnancy, especially in pregnancies beyond the expected date of delivery.

[0034] In a seventh aspect of the present disclosure, a method of slowing or preventing aging or oxidative damage in one or more cells or tissues is provided, the method comprising exposing one or more cells or tissues to an inhibitor of AOX1.

[0035] The inhibitor may act directly or indirectly on AOX1. In an exemplary embodiment, the inhibitor of AOX1 is raloxifene or a G protein-coupled estrogen receptor 1 (GPER1) agonist. An exemplary GPER1 agonist is G-1 ((1-[4-(6-bromobenzo[1,3]dioxol-5yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone).

[0036] In an exemplary embodiment, the tissue is placental tissue. Thus, an inhibitor of AOX1 is administered to a pregnant subject.

[0037] In a further exemplary embodiment, the tissue is skin, kidney, or brain tissue.

[0038] In an eighth aspect of the present disclosure, there is provided a method for treating a disease or condition associated with aging or oxidative damage of one or more cells or tissues, the method comprising administering an inhibitor of AOX1 to a subject in need thereof.

[0039] In a ninth aspect of the present disclosure, there is provided a method of preventing or reducing the risk of post-term pregnancy or stillbirth, the method comprising administering to a pregnant subject an inhibitor of AOX1.

[0040] Further aspects provide for the use of an inhibitor or AOX1 in the manufacture of a medicament for reducing or preventing aging or oxidative damage, treating a disease or condition associated with aging or oxidative damage, or preventing or reducing the risk of post-term pregnancy or stillbirth.

[0041] Aspects and embodiments of the present disclosure are herein described, by way of non-limiting example only, with reference to the following drawings, in which: [Brief description of the drawings]

[0042] [Figure 1] Aldehyde oxidase regulates oxidative damage in placenta associated with stillbirth. Oxidative damage of fatty acids can be demonstrated by 4-hydroxynoneal (4HNE), which is associated with changes in lysosomal and / or autophagosome function. Oxidative damage can also alter intracellular nucleic acid (DNA and / or RNA), which can be demonstrated by the presence of 8-hydroxy-guanosine (8OHdG) or 8-hydroxyguanosine (8HOG). 4HNE, 8OHdG, and 8HOG can indicate placental aging. Aldehyde oxidase can be inhibited by raloxifene and by interacting with G protein-coupled estrogen receptor 1 using agonist G1. [Diagram 2] Relationship between stillbirth and number of continuing pregnancies. Kaplan-Meier plot of number of continuing pregnancies as a function of gestational age, and plot of unexplained stillbirth per 1000 continuing pregnancies; data from Omigbodun and Adewuyi (1997) (J Natl Med Assoc, 89:617) and Sutan et al (2010) (J Perinatol, 30:311-318). The plot shows that the risk of stillbirth increases over time, consistent with the available definition of aging proposed by Johnson et al (1999) (Cell, 96:291-302), and that the number of pregnancies at risk of stillbirth by 41 weeks is relatively small due to previous births. [Diagram 3]DNA / RNA oxidation in overdue and stillborn placentas. The graph illustrates that overdue and stillborn placentas have higher intensity nuclear 8OHdG / 8HOG staining compared to term placentas (p<0.0001 for overdue and p=0.0005 for stillborn, Mann-Whitney test). Open and filled circles represent full-term cesarean section non-delivered placentas (n=10) and full-term vaginally delivered placentas (n=8), respectively. Open and filled squares represent overdue cesarean section placentas (n=5) and overdue vaginally delivered placentas (n=13), respectively. Filled triangles represent late-term vaginally delivered placentas with unknown cause stillbirth (n=4). Each point on the graph represents the average intensity of 8OHdG / 8HOG in 60 nuclei in 6 images per placenta taken at 100x magnification and an optical resolution of 1.4. [Figure 4] Lipid peroxidation was increased in overdue and stillborn placentas. 4HNE intensity was significantly increased in overdue (p<0.0001, Mann-Whitney test) and stillborn placentas (p=0.0013, Mann-Whitney test). Open and closed circles represent non-delivered placentas from term cesarean section (n=21) and term vaginally delivered placentas (n=14), respectively. Open and closed squares represent overdue cesarean section (n=10) and overdue vaginally delivered placentas (n=18), respectively. Closed triangles represent late-term vaginal stillborn placentas of unknown cause (n=4). Each point on the graph represents the average intensity per unit area of ​​six images for an individual placenta taken at 100x magnification and an optical resolution of 1.4. [Diagram 5] Levels of 4HNE in maternal plasma from early (n=17), late (n=26), preeclampsia (PE, n=22), and intrauterine growth restriction (IUGR, n=24) cases. Late, PE, and IUGR groups have significantly higher levels of 4HNE than the early group. Early vs. late, p=0.0016; early vs. PE, p=0.0017; early vs. IUGR, p=0.0016. [Figure 6]Changes in lysosomal distribution in overterm and stillborn placentas. Immunohistochemistry for the lysosomal marker LAMP2 showed that lysosomes were primarily localized at the apical surface of term placentas (e.g., as indicated by the white line) but lysosomal distribution extended to the perinuclear and basal surfaces of syncytiotrophoblasts in overterm (B) and stillborn (C) placentas. Intensity calculations across syncytiotrophoblasts showed that the distribution of LAMP2 in overterm (n=5, Fig. 5F) and stillborn placentas of unknown cause (n=4, Fig. 5G) shifted to the perinuclear and basal surfaces, whereas the distribution of lysosomes in term cesarean (n=5, Fig. 5D) and term vaginally delivered (n=5, Fig. 5E) placentas remained in the apical region of syncytiotrophoblasts. DAPI staining identifies nuclei. In Figures 5D-G, each colored line represents the results for an individual placenta and shows the average intensity of LAMP2 throughout the syncytiotrophoblast in five random sites for each of six individual images per placenta (examples shown by light green lines in 5A, 5B, and 5C). Images were taken at 100x magnification and an optical resolution of 1.4. Scale bar, 20 μm. [Figure 7] Larger autophagosomes are present in overdue and stillborn placentas. NIS-Elements software was used to quantify the size of autophagosomes and measure their diameter in an arbitrary intensity range of 1000-3000, diameter range of 0.2-1 μm, and circularity range of 0.5-1. Analysis showed that overdue and stillborn placentas had significantly larger (p=0.012 and p=0.0019, respectively, Mann-Whitney test) autophagosomes than full-term placentas. Open and filled circles represent full-term cesarean non-delivered placentas (n=ll) and full-term vaginally delivered placentas (n=10), respectively. Open and filled squares represent overdue cesarean placentas (n=8) and overdue vaginally delivered placentas (n=15), respectively. Black triangles represent stillborn placentas of unknown etiology (n=4). Each point on the graph represents the average diameter of LC3B particles in six images taken of each placenta. [Figure 8]Oxidized lipids in autophagosomes from postterm placentas. Representative double-label immunofluorescence staining shows that LC3B, an autophagosome marker, colocalizes with 4HNE, a marker of lipid peroxidation. Dots (pointed by arrows in C) indicate colocalization. DAPI staining indicates nuclei. Original magnification 100x; scale bar 20 μm. [Figure 9] RNA-sequencing data showed that postterm placentas had significantly higher expression of AOX1 mRNA than term placentas. [Figure 10] Role of aldehyde oxidase 1 (AOX1) in the production of 4HNE. Representative double-labeled immunofluorescence staining in overterm (A-C) and stillborn (D-F) placentas showed that AOX1-positive particles colocalized with 4HNE. Dots (pointed by arrows in C and F) indicate the degree of colocalization. Nuclei were stained with DAPI. Real-time PCR showed that AOX1 mRNA expression was increased in overterm (p=0.0097) and stillborn (p=0.012) placentas compared to term placentas (G). Original magnification 100x; scale bar 20 μm. [Figure 11] Pharmacological inhibition of 4HNE production and GPER1 expression in the placenta. 4HNE production (induced by serum starvation) is significantly decreased after treatment of placental explants with the AOX1 inhibitor raloxifene (A) and the membrane estrogen receptor GPER1 agonist G1 (B). Data are mean ± SEM, *p<0.05 (N=6). [Figure 12] Changes in autophagosome size in placental explants cultured in serum-free medium. Immunohistochemical analysis showed that the size of autophagosomes (LC3B-positive particles) increased after 24 h of serum starvation compared to 0 h. Data are presented as mean ± SEM, ***p=0.0002 (N=13). [Figure 13]Detection of GPER1 in different tissues by real-time PCR and Western blotting. Real-time qPCR data showed that GPER1 mRNA was more highly expressed in term placenta than in amnion, chorion, and decidua (A). The expression level of GPER1 mRNA in these tissues was in the following order: decidua < chorion < amnion < placenta (A). These proteins were extracted from breast cancer cell line MCF-7, term placenta, term myometrium, term amnion, term chorion, and term decidua and Western blotting was performed (B). Placenta, myometrium, and MCF-7 cell lines expressed higher amounts of GPER1 than amnion, chorion, or decidua (B). Western blotting data showed that all tissues expressed glycosylated GPER1 (indicated by ** or ***) and non-glycosylated nascent GPER1 (indicated by *). Sypro-ruby staining of the same PVDF membrane was used as an internal loading control (C). [Figure 14] AOX1 mRNA is increased in maternal whole blood from stillbirth cases compared with full-term pregnancies. [Figure 15] Immunostaining for 4HNE in kidney tissue from a 66-year-old subject (A) and a 21-year-old subject (B). All images are at 20x magnification unless otherwise indicated. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, exemplary methods and materials are described.

[0044] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example only, "an element" means one element or more than one element.

[0045] Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise" and variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not to exclude other integers or steps or groups of integers or steps.

[0046] As used herein, the term "subject" includes any mammal, such as humans, non-human primates, livestock animals (e.g., sheep, pigs, cows, horses, donkeys, goats), laboratory animals (e.g., mice, rabbits, rats, guinea pigs, other rodents), and companion animals (e.g., dogs, cats). In a typical embodiment, the subject is a human. Similarly, the term "individual" includes any mammal, such as humans, non-human primates, livestock animals (e.g., sheep, pigs, cows, horses, donkeys, goats), laboratory animals (e.g., mice, rabbits, rats, guinea pigs, other rodents), and companion animals (e.g., dogs, cats). In a typical embodiment, the individual is a human.

[0047] The term "stillbirth" in this specification refers to the death of a fetus before or during birth at about 20 weeks or more of gestation or weighing about 400 g or more at birth (Perinatal Society of Australia and New Zealand Clinical Practice Guideline for Perinatal Mortality; Second Edition, version 2.2, April 2009).

[0048] The term "overdue" refers to a pregnancy that has passed the expected gestational age. In the context of this disclosure, when referring to a human pregnancy, the term "overdue" is used to refer to a pregnancy that is greater than 40 weeks gestation. Overdue pregnancies are sometimes also referred to as post-term pregnancies.

[0049] The term "oxidative stress" as used herein is used interchangeably with the term "oxidative damage" and refers to an imbalance between reactive oxygen species and antioxidant mechanisms, and the damage caused by such an imbalance. Non-limiting examples of oxidative damage include the oxidation of nucleic acids, such as DNA or RNA, which can be detected in a sample, for example, by analysis or measurement of 8-hydroxy-deoxyguanosine or 8-hydroxyguanosine (8OHdG or 8HOG), and the oxidation of lipids, which can be detected in a sample, for example, by measurement of alkenals, such as 4-hydroxynonenal (4HNE). In particular, the term "placental oxidative stress" as used herein refers to oxidative stress that occurs in the placenta. Without wishing to be bound by theory, the inventors propose that increased oxidative stress in the placenta may be associated with placental aging and may result in the placenta's inability to properly support the fetus. Thus, the inventors hypothesize that placental oxidative stress may be associated with an increased risk of stillbirth.

[0050] The term "biomarker" as used herein refers to a naturally occurring biologically functional compound or molecule, such as a gene, a nucleic acid sequence, a protein or fragment thereof, or other metabolite, which has predictive value for the diagnosis of tissue aging in various body tissues, such as the placenta, skin, kidney, and brain, for the diagnosis of preeclampsia, for the diagnosis of intrauterine growth retardation, and for the diagnosis and assessment of risk of post-term pregnancy and stillbirth. Determining the level or activity of a marker in a biological sample may include detection and quantification of the marker itself or its precursors, derivatives, or metabolites. The terms "biomarker" and "marker" may be used interchangeably herein.

[0051] In the context of the present disclosure, a biomarker can be an RNA or other nucleic acid sequence. In embodiments where placental tissue aging and related conditions and effects are assessed, mRNA can be derived from the placenta and measured in maternal blood. Also according to embodiments of the present disclosure is the determination of expression of precursors, derivatives, variants, analogs, and functional fragments of the biomarkers identified herein. A variant of a biomarker includes a molecule that exhibits at least a portion of the functional activity of the biomarker of which it is itself a variant.

[0052] In the context of this disclosure, reference to an increase in expression of a marker in a given sample typically refers to an increase in the expression level of that marker in the sample when compared to the expression level in one or more control or reference samples, or when compared to a baseline measurement of a sample from the same subject. A control or reference sample can be used herein to refer to a sample obtained from one or more individuals without signs of oxidative stress or tissue aging, and / or, in the case of pregnant individuals, without risk of post-term pregnancy or stillbirth.

[0053] In one aspect, the disclosure provides a method for detecting or determining aging of a body tissue, the method comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample obtained from a subject, wherein the level of AOX1 expression or activity determined by the level of the one or more markers is indicative of aging of the tissue.

[0054] A further aspect of the present disclosure provides a method for detecting placental aging, comprising obtaining a biological sample from a pregnant subject and measuring one or more markers of placental AOX1 expression or activity in the biological sample, wherein the level of AOX1 expression or activity or one or more markers is indicative of placental aging.A further aspect provides a method for predicting the risk of stillbirth during pregnancy, comprising obtaining a biological sample from a pregnant subject and measuring one or more markers of placental AOX1 expression or activity in the biological sample, wherein the level of AOX1 expression or activity or one or more markers is indicative of stillbirth risk.

[0055] The inventors' novel discoveries disclosed and exemplified herein, in some embodiments, provide an accurate, cost-effective, and rapid method for predicting the risk of overdue pregnancies or stillbirth. Thus, in exemplary embodiments, disclosed herein is a simple biochemical test that facilitates prediction of risk of stillbirth and identification of therapeutic prophylaxis or preventative therapies for at-risk pregnancies.

[0056] The inventors' novel discoveries disclosed and exemplified herein also provide, in some embodiments, accurate, cost-effective and rapid methods for detecting or assessing tissue aging and for detecting or assessing tissue oxidative damage in various body tissues, including, for example, placenta, skin, kidney and brain tissue.

[0057] We demonstrate herein that dramatic changes occur in placental biochemistry and physiology between 38 and 41 weeks of gestation. In particular, there is increased oxidative damage to DNA and lipids, changes in the location of lysosomes that accumulate at the perinuclear and basal surfaces of syncytiotrophoblasts, the formation of larger autophagosomes associated with oxidized lipids, and increased expression of the enzyme AOX1. The same changes have been observed in placentas associated with stillbirth. Similar changes in lipid oxidation, lysosomal localization, and autophagosome size occur in growth factor-deprived placental explants, and these changes can be blocked by inhibition of AOX1.

[0058] We also demonstrate herein that placental physiological function at 41 weeks shows evidence of decline with many of the hallmarks of aging in other tissues. Thus, the known exponential increase in unexplained intrauterine deaths occurring after 38 weeks of gestation may be the result of placental aging and its diminished ability to function adequately to meet the increasing demands of the growing fetus. This knowledge may impact obstetric practice to ensure that infants are born before the placenta has aged to the point of critical failure.

[0059] As mentioned above, the risk of stillbirth increases with gestational age, especially exponentially after gestational age 38 weeks. Similarly, signs of oxidative damage increase as the placenta ages. However, those skilled in the art will understand that signs of placental ageing and therefore oxidative damage may appear at different times and progress at different rates in different individuals. Therefore, it is not possible to prescribe a specific gestational age at which to begin the method of the present invention, or a specific gestational age at which to begin the method of the present invention, or a number of times during pregnancy at which the method should be utilized. For example, the method of the present disclosure can be performed from about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 weeks of gestation for human subjects. The method can be performed one or more times during pregnancy, for example, every week or every other week. The frequency of testing and monitoring using the methods disclosed herein may increase as the gestational age increases. The appropriate timing for initiation of testing and monitoring according to the present disclosure, as well as the appropriate frequency, can be determined on a case-by-case basis by the skilled recipient without undue burden or need for further invention.

[0060] We also demonstrate herein that our findings extend to tissues other than placental tissue and provide evidence that AOX1 causes oxidative damage in the kidney.

[0061] Without wishing to be bound by theory, the inventors suggest that increased expression or activity of AOX1 in tissues such as placenta, skin, kidney, or brain results in oxidative damage and oxidative stress in the tissue, contributing to tissue aging (Figure 1, in the context of placenta). In the case of placental tissue, placental aging can result in a lack of adequate nutrient delivery to the fetus, causing intrauterine growth retardation and / or stillbirth. The inventors have shown that indicators of placental oxidative stress, such as placental aldehyde oxidase, can be measured in maternal blood, providing a biomarker of placental integrity that can be assayed non-invasively with minimal risk to the fetus. Thus, suitable methods are disclosed herein for assaying risk of stillbirth during pregnancy using biomarkers of placental oxidative stress, such as AOX1 expression. The inventors also demonstrate that such oxidative stress can be prevented by AOX1 inhibition.

[0062] We also note that indicators of placental aging, such as oxidative damage and lysosomal localization, are shared with other pathologies such as Alzheimer's disease, suggesting that aging and oxidative stress in general may be AOX1 related and could be delayed or prevented by AOX1 inhibition.

[0063] In certain embodiments of the present disclosure, the method includes measuring placental AOX1 mRNA in maternal blood. Additional placental oxidative stress biomarkers that are proxies for AOX1 expression or activity include, but are not limited to: lipid peroxidation products such as 4-hydroxynonenal (4HNE) and other hydroxyalkenals, which indicate oxidative damage to lipids; 8-hydroxyguanosine (8OHdG) and 8-hydroxyguanosine (8HOG), which indicate oxidative damage to nucleic acids; and other markers of oxidative stress, such as increased concentrations of malondialdehyde (MDA), isoprostanes, oxysterols, or protein carbonyls.

[0064] The embodiments of the present disclosure include methods for detecting and determining risk of overdue pregnancy and stillbirth, in which an increase in AOX1 mRNA or other markers of AOX1 expression or activity above baseline (typically determined by one or more reference values ​​as described above) indicates placental oxidative stress and an increased risk of overdue pregnancy or stillbirth. Because stillbirth can occur at any stage of pregnancy (by definition, 21 weeks or more of pregnancy or 400g or more in humans), the methods disclosed herein contemplate monitoring the presence and levels of oxidative stress markers disclosed herein in maternal whole blood at various times during pregnancy. Such markers can be detected and measured over the course of pregnancy in humans, for example, at 1 week, 2 weeks, 3 weeks, or 4 weeks intervals from 20 weeks of pregnancy. An increase from baseline in AOX1 mRNA or markers of AOX1 expression or activity would indicate an increased risk of overdue pregnancy or stillbirth.

[0065] The biochemical tests used to determine the level of a biomarker according to the embodiments disclosed herein can be performed using any means known in the art, and the disclosure is not limited by the reference to the means by which the level of the biomarker is determined. The determination of the level of a biomarker may include detection and / or quantification, and the methods and techniques available for such determination are well known to those skilled in the art. Typically, when the biomarker is mRNA, the assay of the present disclosure will be quantitative real-time PCR. Other methods of detecting the biomarkers herein include, but are not limited to, PCR, DNA arrays, microarrays, ligase chain reaction, oligonucleotide ligation assays, cDNA microarrays, next generation sequencing, northern blotting, in situ hybridization, and further statistical analysis to determine differential expression of individuals.

[0066] Suitable methods and techniques for measuring protein biomarkers may include, but are not limited to, the use of spectroscopy, column chromatography, gel electrophoresis, mass spectrometry and protein spot identification, enzyme-linked immunosorbent assay (ELISA), Western blot, image acquisition and analysis (such as magnetic resonance imaging (MRI) spectroscopy, single photon emission computed tomography (SPECT)), immunostaining, HPLC, LC / MA. The biochemical tests used to determine the levels of biomarkers according to the embodiments disclosed herein may be utilized in any suitable environment or setting, such as a hospital, clinic, surgical or medical practice, or pathology laboratory.

[0067] The appropriate biochemical test can be integrated into one or more devices capable of analyzing the desired biomarkers, thereby allowing for some or complete automation of the testing process. A suitable device typically has the ability to receive a biological sample, analyze the level of one or more biomarkers in said sample, and provide data on the level of said biomarkers in real time, thus facilitating analysis, diagnosis, risk assessment, and / or treatment from the bench-to-bedside and point of care. It should be understood that reference to determining the level of expression or the level of a marker is intended to refer to the use of any appropriate technique that will provide information related to the expression level or levels of the desired marker in the relevant tissue of the subject. Thus, these techniques include both in vivo techniques, such as MRI imaging with phosphorus coils, and in vitro techniques that are applied to biological samples extracted from the subject. Other oxidative stress markers, such as 4HNE, 8OHdG, or 8HOG, can be detected by methods well known in the art, such as, for example, fluorescence detection, immunohistochemistry, or chromatographic methods such as HPLC.

[0068] The biological sample obtained from an individual to determine the level of oxidative stress markers can be from any suitable body fluid or tissue. Typically, in the method of the present disclosure, the sample can include blood (such as red blood cells, white blood cells, whole blood, plasma, or serum), urine, amniotic fluid, saliva, or tissue. If the subject is pregnant, the biological sample can be from the mother, placenta, or fetus. In one embodiment, the biological sample is maternal whole blood.

[0069] It is known in the art that fetal cells or nucleic acids can be present in maternal blood. Thus, the biomarkers measured in the methods of the present disclosure can be measured in samples such as free DNA or free RNA, placental cells, fragments of placental cells, exosomes, or microparticles released from the placenta into the maternal circulation.

[0070] If increased AOX1 mRNA or biomarker levels are detected prior to spontaneous labor, physicians can consider available options to reduce the risk of stillbirth. Such options include, for example, induction of labor or Caesarean section if the fetus is at a stage where it is likely to be alive when born. If increased AOX1 mRNA or biomarker levels are detected at an age where the baby is considered preterm, options to delay placental aging or lengthen gestation can be considered. As disclosed and exemplified herein, options may include, for example, treating the pregnant mother with antioxidant treatment or one or more AOX1 inhibitors. As discussed further below, examples of suitable AOX1 inhibitors include raloxifene or agonists of G-protein-coupled estrogen receptor 1 (GPER1), such as G-1.

[0071] The present disclosure provides that the marker of AOX1 expression or activity can be determined or measured in combination with one or more clinical assessments as an additional indicator of tissue aging.For example, in pregnant subjects, clinical assessments such as changes in fetal movement, fetal growth measurement, or altered Doppler study of placental artery, placental vein, or fetal cerebral artery can be used in combination with the marker of AOX1 expression or activity to assess placental aging, risk of stillbirth, need for intervention to prevent stillbirth, and placental oxidative stress.The clinical assessment appropriate to the context can be easily determined by those skilled in the art.

[0072] The present disclosure also provides kits suitable for use according to the methods of the present disclosure. Such kits include, for example, prognostic kits for assaying biological samples, including reagents for detecting the expression levels of the discriminatory biomarkers disclosed herein (such as AOX1 mRNA, 4HNE, 8HOG, and 8OHdG). Kits according to the present disclosure may also include other components necessary for carrying out the methods of the present disclosure, such as buffers and / or diluents. The kits typically include containers for housing the various components, and instructions for using the components of the kit in the methods of the present disclosure.

[0073] The present disclosure also contemplates administration of therapeutic agents to prevent oxidative damage or tissue aging. In some embodiments, in cases of oxidative damage or placental aging during pregnancy that have been found to be associated with a high risk of stillbirth, including cases where delivery is not possible due to extreme prematurity, appropriate therapeutic agents can be administered during pregnancy. Without wishing to be bound by theory, the inventors suggest that the placenta may provide a tractable model of human tissue aging that ages on its own over a nine-month period. Herein, the inventors demonstrate changes in placental oxidative stress markers and lysosomal location that resemble those in aging diseases such as Alzheimer's and Huntington's (see examples). The similarities in oxidative damage and lysosymal distribution between placental aging and aging in neurodegenerative diseases suggest that similar aging mechanisms may exist in these conditions. Thus, it is contemplated by the present disclosure that aging due to oxidative stress, as well as diseases and conditions in which oxidative damage is a cause, can be prevented, delayed, or treated with administration of GPER1 agonists or AOX1 inhibitors such as raloxifene, and other inhibitors of AOX1 or GPER1 agonists as contemplated herein.

[0074] Therefore, in other embodiments, suitable therapeutic agents can be administered to prevent, delay, slow, retard or treat aging and oxidative stress or damage in skin, kidney or brain tissue.The oxidative stress and oxidative damage of such tissues can be the result of the aging process alone or can be caused, accelerated or exacerbated by various other factors.By way of example only, oxidative damage and aging of the skin can be associated with prolonged exposure to sunlight or sunburn, oxidative damage and aging of the kidney can be associated with acute or chronic kidney damage or kidney disease, smoking and drug abuse, hypertension, dyslipidemia, obesity and inflammatory disease, and oxidative damage and aging of the brain can be associated with brain trauma or injury, or neurodegenerative conditions such as memory loss, Alzheimer's disease and Parkinson's disease.

[0075] According to the method of the present disclosure, the therapeutic agents used according to the present disclosure include, for example, inhibitors of AOX1, including, but not limited to, raloxifene and G protein-coupled receptor 1 (GPER1) agonists. For example, in an embodiment of the present disclosure, agonists of GPER1 can be used to reduce or prevent oxidative stress in the placenta. One particularly suitable agonist of GPER1 used according to the present disclosure is G-1, (1-[4-(6-bromobenzo[1,3]dioxol-5yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone). G-1 is a cell-permeable nonsteroidal dihydroquinoline compound that acts as a high affinity GPER agonist.

[0076] However, those skilled in the art will understand that the scope of the present disclosure is not so limited and other AOX1 inhibitors or drugs that can directly or indirectly activate GPER1 receptor or its downstream pathways can be used.Other inhibitors of AOX1 that are also suitable for use in the methods of the present disclosure include, for example, tamoxifen, estradiol, ethinylestradiol, phenothiazines, tricyclic antidepressants, tricyclic atypical antipsychotics, dihydropyridine calcium channel blockers, loratidine, cyclobenzaprine, amodiaquine, maprotiline, ondansetron, propafenone, domperidone, quinacrine, ketoconazole, verapamil, tacrine, and salmeterol.

[0077] Additional therapies that can be used in combination with, or instead of, therapeutic compounds targeting GPER1 or AOX1 include antioxidant molecules, compounds or treatments, such as thiols, ascorbic acid, or phenols (such as polyphenols), superoxide dismutase, catalase, peroxiredoxin, thioredoxin, glutathione, carotene, α-tocopherol, resveratrol, and flavonoids.

[0078] For purposes of this disclosure, compositions containing therapeutic agents for administration can be prepared by methods well known to those skilled in the art. The compositions may therefore include pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants. The carriers, diluents, excipients, and adjuvants must be "acceptable" in terms of being compatible with the other components of the composition and not harmful to the subject ingesting the composition. The pharma- ceutically acceptable carriers, diluents, excipients, and / or adjuvants to be used may depend on the intended route of administration of the composition and will be well known to those skilled in the art. The compositions may be administered via any convenient or suitable route, including, for example, topically, orally, nasally, or other mucosal routes, or parenterally, such as subcutaneously, intramuscularly, or intra-arterially. The route of administration will depend on several factors, including the tissue to be treated. Similarly, the form or vehicle in which the composition is administered will depend on many factors, including the tissue to be treated. Exemplary forms may include injectable solutions or suspensions, lotions, liniments, gels, creams, ointments, foams, oils, powders, and the like for topical administration, as well as tablets, troches, capsules, elixirs, suspensions, syrups, cachets, granules, powders, gels, pastes, solutions, suspensions, soluble sachets, caplets, lozenges, effervescent tablets, chewable tablets, multi-layer tablets, and the like for oral administration.

[0079] In an exemplary embodiment for administration of a composition for treating, preventing, slowing, retarding, or delaying skin aging or oxidative damage to the skin, a suitable AOX1 inhibitor or GPER agonist disclosed herein can be formulated into a liniment, gel, cream, ointment, foam, oil, or the like for topical application to the skin. Such a formulation can be applied directly to the skin or by adding the formulation to a bath. The formulation can also include sunscreen, vitamin E, or other suitable ingredients, for example, to minimize the effects of ultraviolet light and / or to help moisturize and / or repair the skin.

[0080] Examples of pharma- ceutically acceptable carriers, diluents, excipients, and adjuvants include, but are not limited to, demineralized or distilled water; saline; peanut oil, safflower oil, olive oil, cottonseed oil, corn oil, sesame oil, arachis oil, or coconut oil; oils of vegetable origin such as safflower oil, olive oil, cottonseed oil, corn oil, sesame oil; silicone oils including polysiloxanes such as methylpolysiloxane, phenylpolysiloxane, and methylphenylpolysorboxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin, or squalane; cellulose derivatives such as methylcellulose, ethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, or hydroxypropylmethylcellulose; lower alkanols such as ethanol or isopropanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols such as polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3-butylene glycol, or glycerin; fatty acid esters such as isopropyl palmitate, isopropyl myristate, or ethyl oleate; polyvinylpyridone; agar; carrageenan; gum tragacanth or acacia, and petrolatum.

[0081] The reference in this specification to any prior publication (or information derived therefrom), or to any known matter, is not, and should not be taken as, an acknowledgment or admission, or any form of suggestion, that such prior publication (or information derived therefrom) or any known matter forms part of the common general knowledge in the field to which this specification pertains.

[0082] The present disclosure will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the disclosure. EXAMPLES

[0083] The following examples are illustrative of the present disclosure and should not be construed as in any way limiting the general nature of the disclosure described throughout the specification.

[0084] Common methods Tissue Ethics, Collection, and Processing The study was approved by the Human Research Ethics Committee of Hunter New England Health Services and University of Newcastle, NSW, Australia. Human placentas were collected after written informed consent was obtained from patients by midwives. Placentas were collected from women 38-39 weeks pregnant (term) who had previously had a normal vaginal birth and delivered by cesarean section due to previous cesarean section, women 41 weeks pregnant or older who had previously had a normal vaginal birth and delivered by cesarean section, and women who had previously had a stillbirth and delivered vaginally. Placentas were collected immediately after delivery and processed without delay. Villous tissue was collected from multiple sites and prepared for histology and RNA extraction. For each placenta, tissue was obtained from at least five different regions of the placenta and 4-5 mm below the chorionic plate. Samples from individual placentas were immediately frozen under liquid nitrogen and stored at -80°C until further experiments. For histological studies, tissues were fixed in 2% formaldehyde for 24 hours, stored in 50% ethanol at room temperature (RT), and embedded in paraffin. To form placenta rolls, 2 cm strips of chorioamnion were excised from the periphery of the placenta, while keeping a small amount of placenta attached to the membrane. The strip was wrapped around a pair of forceps, leaving residual placenta in the center of the cylindrical roll. The cylindrical roll was then cut perpendicular to the cylindrical axis to obtain 4 mm thick sections. Tissues were then fixed in formalin and mounted in paraffin blocks. Placentas from patients with infection, diabetes, preeclampsia, placenta previa, intrauterine growth retardation, or abruption were excluded.

[0085] Culture of placental explants For in vitro experiments, human term placentas (38-39 weeks gestation) were obtained from women with normal singleton pregnancies without symptoms of labor after elective (planned repeat) Caesarean section. Placentas were harvested immediately after delivery and prepared for explant culture. Placental villous tissue was randomly sampled from different regions of the placenta and 4-5 mm below the chorionic plate. The tissue was washed several times with Dulbecco's phosphate buffered saline (DPBS) under sterile conditions to remove excess blood. Approximately 2 mm 3 villous explants were excised and placed in 100 x 20 mm culture dishes (30 pieces / dish) containing 25 ml of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v / v) fetal bovine serum (FBS), 2 mM L-glutamine, 1% Na-pyruvate, 1% penicillin / streptomycin (100x) solution, and cultured in a cell culture chamber for 24 hours at a temperature of 37°C, while maintaining 95% air (20% oxygen) and 5% CO2. On the second day, the villous explants were transferred to 30 ml of fresh growth medium and incubated in the cell culture chamber for 90 minutes. After this, the tissue was washed with DMEM without FBS (referred to as "serum-free medium" or "growth factor-deficient medium"). Six to seven villous tissues weighing approximately 400 mg were then transferred to culture dishes (60 × 15 mm) containing 6 ml of serum-free medium with or without pharmacological agents, such as raloxifene (1 nM) and the GPER1 agonist G1 (1 nM), for a subsequent incubation of up to 24 h. At the end of 24 h, some tissues were fixed in 2% formaldehyde, routinely processed for histology, embedded in paraffin wax, and some tissues were immediately frozen in liquid nitrogen and stored at -80 °C until further experiments. For each placental explant culture, a sample was collected at "0" time, i.e. before incubation in serum-free medium, formalin fixed, and stored frozen at -80 °C until further experiments.

[0086] Western blotting Western blotting was performed according to Maiti, K et al (2011, Endocrinology, 152:2448-2455). Placental samples (1 g) were ground under liquid nitrogen. Aliquots of 100 mg of placental tissue were homogenized in 1 mL of lysis buffer (phosphate-buffered saline (PBS), 1% Triton-X-100, 0.1% Brij-35, 1x protease inhibitors, 1x phosphatase inhibitors, pH 7.4). Protein concentrations of each placental extract were measured using a BCA protein assay kit, and 40 μg of placental extract was separated by electrophoresis on NuPage bis-tris precast 12-well gels at a constant voltage of 200 V for 50 min. Separated proteins were transferred to nitrocellulose membranes using a Novex transfer system for 70 min and blocked overnight with 1% bovine serum albumin (BSA) in Tris-buffered saline (TBST) containing 0.1% Tween-20. The membranes were then incubated with primary antibodies in 1% BSA in TBST for 2 h, then washed three times with TBST, and then incubated with HRP-conjugated secondary antibodies in 1% BSA in TBST for 1 h. After three further washes with TBST, immunoreactive bands were developed with Luminata reagent and detected using an Intelligent Dark Box LAS-3000 Imager (Fuji Photo Film, Tokyo, Japan).

[0087] Detection of 4HNE in maternal plasma For detection and quantification of 4HNE protein adducts in maternal plasma, we used OxiSelect™ HNE Adduct Competitive ELISA Kit (Cell Biolabs Inc, STA-838). This assay is based on the competition between HNE conjugates and anti-HNE antibodies against HNE protein. In this assay, HNE conjugates are first coated onto an ELISA plate. Then, unknown HNE protein samples or HNE-BSA standards are added to the HNE conjugate resorption ELISA plate. After a short incubation, anti-HNE antibodies are added, followed by secondary antibodies (HRP conjugates). The amount of HNE protein adducts in unknown samples was estimated from a given HNE-BSA standard curve.

[0088] In this assay, first, HNE conjugate was coated onto a 96-well plate and incubated overnight at 4°C. HNE conjugate was removed and wells were rinsed twice with 1x PBS. Assay diluent was added to each well, blocked for 1 hour at room temperature, and then transferred to 4°C until use. Immediately prior to use, assay diluent was removed and 50 μl of maternal plasma sample and HNE-BSA standard were added. Plates were then incubated for 10 minutes at room temperature on an orbital shaker. Diluted anti-HNE antibody was added to each well and incubated for 2 hours at room temperature on an orbital shaker. Plates were then washed three times with 1x wash buffer, aspirating thoroughly between each wash. Diluted HRP-conjugated secondary antibody was added to all wells and incubated for 1 hour at room temperature on an orbital shaker. Strip wells were then washed an additional three times with 1x wash buffer. Substrate solution was added to each well and incubated for 2-5 minutes at room temperature on an orbital shaker, and color change was monitored. Stop solution was added to each well to stop the enzyme reaction. The absorbance of each well was read on a microplate reader (SPECTROstar Nano, BMG LABTECH) using 450 nm as the primary wavelength. The content of HNE-protein adducts in unknown samples was determined by comparison with a predefined HNE-BSA standard curve using GraphPad Prism software. Results were graphed and statistical analysis was performed using GraphPad Prism software.

[0089] immunohistochemistry 6 μm paraffin placenta sections were deparaffinized, hydrated, and then heated in Tris-EDTA buffer (pH 9) in a microwave oven for antigen retrieval. Sections were blocked with 1% BSA in TBST for 1 h at room temperature. Sections were incubated with primary antibodies overnight, washed three times with TBST, and then incubated with Alexa-conjugated secondary antibodies for 90 min. Sections were mounted with antifade solution with DAPI. Fluorescent photographs in Figures 3-7, 9, and 11 were taken with a Nikon eclipse 90i confocal microscope. Fluorescent photograph in Figure 10 was taken with a Nikon eclipse Ti fluorescent microscope.

[0090] RNA isolation and real-time PCR Placental tissue was ground under liquid nitrogen. Approximately 100 mg of ground placental tissue was homogenized in 2 ml of Trizol reagent by Ultra Turrax homogenizer. Total RNA was extracted from Trizol extract by Direct-zol™ RNA MiniPrep. RNA was treated with DNAse and purified with RNA Clean&Concentrator™-5 kit. RNA quality was monitored by running DNAse-treated samples on agarose gels containing ethidium bromide in 1×TAE buffer. Purified RNA was used to generate cDNA using SuperScript® III First-Strand Synthesis System kit. This cDNA was used to perform real-time PCR with Taqman Gene Expression Master Mix containing Taqman primers for aldehyde oxidase 1 (AOX1) and internal control 18s ribosomal RNA to quantify AOX1 mRNA. SyBr green master mix was used to quantitate G protein-coupled receptor 1 (GPER1) mRNA relative to β-actin as an internal control using an Applied Biosystem 7500 PCR system.

[0091] GPER1 primers were 5'-CGTCCTGTGCACCTTCATGT-3' (forward, SEQ ID NO: 1) and 5'-AGCTCATCCAGGTGAGGAAGAA-3' (reverse, SEQ ID NO: 2). AOX1 primers were obtained from Thermo-fisher Scientific (CAT: 4331182, Assay number: Hs00154079_m1). The AOX1 TaqMan assay was designed to detect an 84 bp amplicon from base 3270 of NM_001159.3 (herein SEQ ID NO: 3) at the exon 27 / 28 boundary.

[0092] statistical analysis Sample numbers are indicated in the individual figure legends. Data in Figures 3, 4, 6, 9, and 12 were analyzed using the Mann-Whitney test (two way) and results are presented as scatter plots showing median or standard error. Data in Figures 10 and 11 were analyzed using the Wilcoxon matched-pairs signed-rank test. All p-values ​​were calculated using Graphpad Prism software.

[0093] Example 1 - Relationship between risk of stillbirth and gestational age To illustrate the relationship between risk of stillbirth and gestational age, we created a Kaplan-Meier plot of data on human gestational age in a population with relatively low levels of medical intervention by Omigbodun and Adewuyi (1997, J Natl Med Assoc, 89:617) and combined this with data on risk of stillbirth per 1000 ongoing pregnancies by Sutan et al. (2010, J Perinatol, 30:311-318) (Figure 2). The data show that stillbirth is consistent with the aging etiology defined by Johnson et al. (1999, Cell, 96:291-302).

[0094] Example 2 - DNA / RNA and lipid oxidation in placental tissue Because oxidative damage has been observed in many aging tissues, we looked for evidence of placental DNA / RNA oxidation as measured by 8-hydroxy-deoxyguanosine / 8-hydroxyguanosine (8OHdG / 8HOG) as a marker of DNA / RNA oxidation. Immunohistochemistry (IHC) for 8OHdG / 8HOG was performed on placentas, and the mean intensity of 8OHdG / 8HOG staining in nuclei / frames demonstrated a significant increase in DNA / RNA oxidation in placentas associated with overterm and stillbirths (Figure 3).

[0095] Increased DNA oxidation suggested free radical damage that may also lead to lipid peroxidation. Lipid peroxidation, as measured by the production of 4-hydroxynonenal (4HNE), has been observed to be increased in Alzheimer's disease (Markesbery and Lovell, 1998, Neurobiol Aging, 19:33-36). Therefore, we performed immunohistochemistry for 4HNE in overterm, stillborn, and term placental tissues. This revealed a marked increase in 4HNE staining in overterm syncytiotrophoblasts, which was also observed in the placentas associated with stillbirths shown in Figure 4. The high levels of 8OHdG / 8HOG and 4HNE in overterm and stillborn placentas suggest that placental aging may have occurred in these placentas.

[0096] We also examined 4HNE levels in maternal plasma using a commercially available ELISA kit in cases of preterm birth, late birth (post-term birth), pre-eclampsia, and intrauterine growth retardation (IUGR). 4HNE levels were found to be significantly higher in each of the cases of post-term birth, pre-eclampsia, and IUGR when compared to preterm (Figure 5). Post-term birth, pre-eclampsia, and IUGR are all known to be associated with an increased risk of stillbirth.

[0097] Example 3 - Lysosome trafficking and clustering in postterm and stillborn placentas Misfolded proteins and damaged mitochondria are normally recycled in autophagosomes in a process that involves autophagosome fusion with proteolytic enzymes containing lysosomes. The accumulation of abnormal proteins, such as tau and amyloid proteins in Alzheimer's disease and mutant huntin in Huntington's disease, is thought to play a role in aging, especially brain aging. In Huntington's disease, the distribution of lysosomes in neurons is altered, with increased perinuclear accumulation of lysosomes. We analyzed the distribution of lysosomes in placenta by immunohistochemistry using the lysosomal marker lysosome-associated membrane protein-2 (LAMP2). This showed lysosomes located at the apical surface of syncytiotrophoblasts in full-term placentas (Figures 6A, 6D, and 6E), whereas lysosomes were displaced to the perinuclear and basal surfaces in overterm and stillborn placentas (Figures 6B, 6C, 6F, and 6G).

[0098] The current data demonstrate a striking accumulation of particles positive for the lysosomal marker LAMP2 at the perinuclear and basal surfaces of syncytiotrophoblast cells in placentas associated with overterm and stillbirth.

[0099] Example 4-4Larger autophagosomes containing HNE are present in post-term placentas and in placentas associated with stillbirth Inhibition of autophagosome function through failure to fuse with lysosomes results in an increase in the size of the autophagosome. This process leads to the inhibition of overall autophagy function seen in Alzheimer's disease, Danon disease, and neurodegeneration. In the current study, we detected autophagosomes using immunohistochemistry with an antibody against LC3B. A significant increase in the size of autophagosomes was observed in both postterm and stillbirth-associated placentas compared to full-term placentas (Figure 7). Double-labeled immunofluorescence staining showed that larger autophagosomes in postterm and stillbirth placentas contained 4HNE, a product of lipid peroxidation (Figure 8).

[0100] Autophagy involves the fusion of acidic lysosomes with autophagosomes. Current data show that stillborn and post-term placentas contain larger autophagosomes than term placentas, suggesting an inhibition of the autophagy process in these placentas. These data further show that upon failure of fusion, autophagosomes are coated with oxidized lipids in the form of 4HNE. Such impairment in autophagosome function may result in the accumulation of abnormal proteins and impaired function of syncytiotrophoblasts.

[0101] Example 5 - Role of aldehyde oxidase 1 (AOX1) in oxidative damage in the placenta Using methods well known to those skilled in the art, we sequenced RNA isolated from six term and six postterm placentas. Analysis of the RNA sequencing data showed that of 20,111 genes expressed in the placenta, aldehyde oxidase 1 (AOX1) was significantly increased in postterm placentas compared to term placentas (Figure 9).

[0102] AOX1 is a molybdoflavoenzyme that oxidizes various aldehydes, including 4HNE, to the corresponding acids and peroxides. We then tested the hypothesis that AOX1 is involved in the generation of the increased 4HNE observed in overterm and stillbirth-associated placentas. Dual-label fluorescent IHC showed that AOX1 colocalized with 4HNE-positive particles in overterm (FIGS. 10A-C) and stillbirth placentas (FIGS. 10D-F). Furthermore, real-time qPCR using Life Technologies TaqMan assay Hs00154079_m1 confirmed that overterm and stillbirth placentas expressed significantly higher mRNA for AOX1 than term placentas (FIG. 10G). These data support the notion that AOX1 may play a role in the oxidative damage that occurs in postterm and stillbirth-associated placentas.

[0103] Example 6 - Pharmacological inhibition of 4HNE production using placental explant cultures The current data provide clear evidence of increased lipid oxidation, abnormal lysosome-autophagosome interactions, and increased AOX1 expression in syncytiotrophoblasts of postterm and stillborn placentas. To determine whether these events are causally related, we developed a placental explant culture system using term placental tissue cultured in serum-free (growth factor-deprived) medium. IHC showed that serum deprivation significantly increased the production of 4HNE after 24 hours of incubation (Figures 11A and 11B). A significant increase in the size of autophagosomes was also seen after 24 hours of incubation in serum-free medium (Figures 12A and 12B), suggesting inhibition of autophagy due to oxidative damage at 24 hours, as observed in stillborn and postterm placentas. AOX1 mRNA was increased at 24 hours, suggesting the involvement of AOX1 in oxidative damage.

[0104] We attempted to determine the causal relationship between the occurrence of lipid oxidation observed when placental explants were cultured in the absence of serum and AOX1. The GPER agonist G-1 was used to inhibit aldehyde oxidase. Raloxifene, a potent AOX1 inhibitor, was also used. G-1 was chosen because we detected GPER expression on the apical surface of syncytiotrophoblasts (Figure 11C and Figure 11D), and GPER1 agonists have been shown to inhibit the production of 4HNE in the kidney (Lindsey et al., 2011, Hypertension, 58:665-671). Both raloxifene and G-1 inhibited the production of 4HNE in serum-starved placental explants after 24 hours of treatment (Figure 11A and Figure 11B), demonstrating that these compositions can also prevent lipid oxidative damage and abnormalities in autophagosome size and lysosome location (Figure 12).

[0105] Example 7 - Presence of cell surface estrogen receptor GPER1 on the apical surface of syncytiotrophoblasts Since G-1 had a clear effect in placental explant cultures, we characterized GPER1 expression in placental tissues. Expression of GPER1 in sections of placental rolls detected by fluorescent immunohistochemistry showed that GPER1 was expressed in placental villi (data not shown), and at higher magnification (100x), it was localized to the apical surface of placental villi, whereas full-term amnion, chorion, and decidua showed little GPER1 expression (data not shown). Fluorescent immunostaining with an antibody against LC3B showed changes in the size of autophagosomes in placental explants after serum starvation (Figure 12).

[0106] GPER1 primers were provided by Invitrogen: GPER1 forward primer 5'-CGTCCTGTGCACCTTCATGT-3' (SEQ ID NO: 1) and GPER1 reverse primer 5'-AGCTCATCCAGGTGAGGAAGAA-3' (SEQ ID NO: 2). Real-time PCR of GPER1 showed that placental villi had significantly higher expression of GPER1 than amnion, chorion, and decidua (Figure 13A). Western blot of GPER1 confirmed that the protein level of GPER1 in placental villous tissue was higher than amnion, chorion, and decidua (Figure 13B).

[0107] The presence of the cell surface estrogen receptor GPER on the apical membrane of syncytiotrophoblasts is a novel finding, suggesting that this receptor may play a role in regulating oxidative damage in the placenta. The urine of pregnant women with fetuses with postmature pregnancy syndrome has been shown to have a lower estrogen:creatinine ratio than women with normal fetuses (Rayburn et al., 1982, Obstet Gynecol, 60:148-153). These data support the possibility that low estrogen concentrations may lead to reduced GPER-mediated inhibition of AOX1 and, as a result, oxidative damage and dysfunction of the placenta.

[0108] Example 8 - Detection of AOX1 mRNA in maternal blood Fetal AOX1 mRNA was detected in maternal blood by methods well known to those skilled in the art. Briefly, maternal blood samples were collected in PAXgene® Blood RNA Tubes. Blood samples were stored at -30°C until used for RNA isolation. Total RNA was isolated in 2.5 ml maternal whole blood samples using the PAXgene Blood miRNA Kit and the fully automated RNA isolation system QIAcube (Qiagen). The quality of RNA from the samples was confirmed by running the RNA samples on a bioanalyzer (Agilent Technologies). A ratio value of 28S to 18S greater than 1 was considered as good quality RNA obtained from whole blood. Total RNA was treated with RNAse-free DNAse before being used for cDNA preparation. cDNA was prepared from total RNA using the SuperScript® III First-Strand Synthesis System (Life technologies). AOX1 mRNA was quantified using cDNA using the Taqman gene expression system and a 7500 applied biosystem PCR machine with human 18S ribosomal RNA as an internal control.

[0109] Since most of the AOX1 mRNA in maternal blood originates from the placenta, maternal blood AOX1 mRNA can be used as an indicator of placental oxidative stress. We measured maternal blood AOX1 mRNA in seven mothers at term (completed gestational age 37-39 weeks) and blood samples from two pregnant women who had stillbirths at 31 and 36 weeks of gestation. The mean amount of AOX1 mRNA was significantly increased in maternal blood from stillbirths compared to full-term pregnancies (Figure 14).

[0110] Example 9 - Renal aldehyde oxidase-mediated aging Kidney tissues from 21-year-old and 66-year-old subjects were stained for 4HNE as a marker of oxidized lipids generated by aldehyde oxidase. The results shown in Figure 15 demonstrate that aldehyde oxidase causes oxidative damage in the kidney, which is a marker of aging. Thus, tissues that express aldehyde oxidase may be aged by oxidative damage.

Claims

1. Use of an inhibitor of aldehyde oxidase 1 (AOX1) in the manufacture of a medicament for treating or preventing a skin condition associated with aging or oxidative damage to the skin, wherein the skin expresses AOX1, the medicament is formulated for topical administration, and the AOX1 inhibitor is raloxifene or the G protein-coupled estrogen receptor 1 (GPER1) agonist G-1.

2. Use of an inhibitor of AOX1 in the manufacture of a medicament for inhibiting, delaying or slowing aging or oxidative damage in the skin of a subject, wherein the skin expresses AOX1, the medicament being formulated for topical administration, and the AOX1 inhibitor is raloxifene or the G protein-coupled estrogen receptor 1 (GPER1) agonist G-1.

3. The use described in claim 1 or 2, wherein the medicament is formulated for administration in the form of a liniment, gel, cream, ointment, foam or oil.

4. Use of an inhibitor of aldehyde oxidase 1 (AOX1) in the manufacture of a medicament for treating or preventing a disease or condition associated with aging or oxidative damage to human placental tissue, wherein the AOX1 inhibitor is raloxifene or the G protein-coupled estrogen receptor 1 (GPER1) agonist G-1.

5. The use described in claim 4, wherein the disease or condition associated with placental aging is pre-eclampsia, intrauterine growth retardation, post-term pregnancy or stillbirth.